We hypothesized that interferon-alpha (IFN-α) would enhance the apoptotic activity of bortezomib on melanoma cells. Combined treatment with bortezomib and IFN-α induced synergistic apoptosis in melanoma and other solid tumor cell lines. Apoptosis was associated with processing of procaspases-3, -7, -8, -9, and with cleavage of Bid and PARP. Bortezomib plus IFN-α was effective at inducing apoptosis in melanoma cells that over-expressed Bcl-2 or Mcl-1, suggesting that this treatment combination can overcome mitochondrial pathways of cell survival and resistance to apoptosis. The pro-apoptotic effects of this treatment combination were abrogated by a caspase-8 inhibitor, led to increased association of Fas and FADD prior to the onset of cell death, and were significantly reduced in cells transfected with a dominant-negative FADD construct or siRNA targeting Fas. These data suggest that bortezomib and IFN-α act through the extrinsic pathway of apoptosis via FADD-induced caspase-8 activation to initiate cell death. Finally, bortezomib and IFN-α displayed statistically significant anti-tumor activity as compared to either agent alone in both the B16 murine model of melanoma and in athymic mice bearing human A375 xenografts. These data support the future clinical development of bortezomib and IFN-α for malignant melanoma.
INTRODUCTION
Bortezomib is a novel anti-tumor compound that specifically and reversibly inhibits the 26S proteasome. The proteasome plays a critical role in the ordered, temporal degradation of transcription factors, cyclins and cyclin dependent kinase (CDK) inhibitors required for cell cycle progression in malignant and normal cells (1) . Bortezomib has in vitro activity against a variety of tumor cell types (2) (3) (4) (5) . As a single agent, bortezomib has an acceptable toxicity profile and has demonstrated activity in patients with advanced multiple myeloma, nonHodgkin's lymphoma, mantle cell lymphoma and non-small cell lung cancer (6) (7) (8) (9) . Bortezomib has also shown some clinical activity in other solid tumors, including advanced renal cell carcinoma (10, 11) . Single agent bortezomib was tested in a phase II study of malignant melanoma, however, no responses were achieved when the drug was administered at 1.5 mg/ m 2 i.v. twice weekly for two weeks out of every three (12) . Based on these studies, current research efforts in solid tumors are now focused on the use of bortezomib in combination with other pro-apoptotic agents (13) (14) (15) (16) .
Recombinant interferon-alpha (IFN-α) has been used in the treatment of malignant melanoma and renal cell carcinoma (RCC) and mediates the regression of metastatic disease in about 10-15% of patients (17, 18) . Studies investigating the pro-apoptotic effects of IFN-α in tumor cell lines indicate that this cytokine can activate both the intrinsic and extrinsic pathways of apoptosis (19) (20) (21) (22) (23) (24) . Of note, IFN-α has been shown to increase the expression of cell cycle regulatory proteins (e.g. p21) in malignant cells, and proteins involved in the death receptor cascade (Fas, TRAIL), thereby sensitizing cells to apoptotic stimuli (25, 26) . These observations suggested that IFN-α therapy might enhance the pro-apoptotic effects of proteasome inhibition in the setting of melanoma.
In the present study, we have demonstrated that treatment of melanoma cells with bortezomib and IFN-α synergistically induced apoptotic cell death via FADD-dependent activation of caspase-8. Importantly, this treatment combination could effectively induce apoptosis in cells that over-expressed Bcl-2 or Mcl-1, two relevant pathways of cellular survival and resistance to apoptosis in melanoma cells.
MATERIALS AND METHODS

Cell Lines
The B16F1 (murine) A. Taghiev (University of Iowa) (27) . Fas-specific siRNA and negative control siRNA constructs were purchased from Santa Cruz Biotechnology, Inc. (Santa Cruz, CA).
Analysis of Apoptosis Via Annexin V/Propidium Iodide (PI) Staining
Phosphatidyl serine exposure was assessed in tumor cells by flow cytometry using APCAnnexin V and propidium iodide (PI; BD Pharmingen, San Diego, CA) as previously described (28) . Each analysis was performed utilizing at least 10,000 events.
Immunoblot Analysis
Immunoblots were prepared as previously described and probed with antibodies specific for FADD, Fas, FasL, Bax (Santa Cruz Biotechnology, Santa Cruz, CA), human Bid (a BH3-only member of the Bcl-2 family), Bcl-2, Mcl-1, Bcl-xL, caspase-3, -7, -8, cleaved caspase-7, poly (ADP-ribose) polymerase (PARP) (Cell Signaling Technology), caspase-9 (Upstate Cell Signaling Solutions, San Francisco, CA), Noxa (Calbiochem, San Diego, CA) or β-actin (Sigma) (29) . Following incubation with the appropriate horseradishperoxidase-conjugated secondary Ab, immune complexes were detected using the ECL Plus detection kit (Amersham Biosciences, Ayesbury, UK) and analyzed by quantitative densitometry using Optimas 6.51 image analysis software (Media Cybernetics, Carlsbad, CA).
Proliferation Assays
The effects of bortezomib and IFN-α on cell proliferation were tested in murine melanoma cell lines (B16F1, JB/MS), human melanoma cell lines (HT144, MEL 39), and human RCC cell lines (RC-45, RC-54). Cell proliferation was measured as optical density (O.D.) at 570 nm using the MTT Cell Proliferation Assay Kit according to manufacturer's instructions (ATCC, Manassas, VA). All assays were performed in triplicate as previously described (19) .
Murine Tumor Models and Treatments
An i.p. tumor model of malignant melanoma was employed to determine whether treatment with the combination of bortezomib and IFN-α was superior in anti-tumor activity to either agent alone (19) . Immune-competent, female C57BL/6 mice (n = 11 mice/group; 6-8 weeks of age; Taconic Farms, Inc., Germantown, NY) were injected i.p. on day 0 with 10 6 B16F1 murine melanoma cells. Beginning the next day mice received PBS, bortezomib (1.0 mg/kg twice weekly i.p.), muIFN-α (2×10 4 U/d i.p.), or IFN-α and bortezomib combined and monitored for survival. Human xenograft studies were conducted similar to other published reports investigating in vivo activity of bortezomib in athymic mice (5, 16) . Briefly, female Balb/c nu/nu (athymic) mice (Taconic Farms, Inc.) were injected subcutaneously (s. Bi-dimensional tumor measurements were obtained twice weekly using microcalipers. The weight of all animals receiving bortezomib or IFN-α and bortezomib combined was monitored for dosing and to assess toxicity throughout the study. Histologic analysis of apoptosis in formalin-fixed paraffin-embedded (FFPE) tumor xenografts was conducted using terminal deoxynucleotidyl transferase-mediated dUTP-biotin nick end labeling (TUNEL) as recommended by the manufacturer (Chemicon, Inc.). CD31 immunostaining was also used to evaluate angiogenesis in FFPE tumor xenografts. All samples were analyzed in a blinded fashion by an experienced pathologist (Dr. Ray Chaudhury), and the number of cells positive for each marker of interested were quantitated per 10 high-power fields.
Statistical Analysis
Analysis of variance (ANOVA) was used to determine if the two drugs (bortezomib and IFN-α) reduced cell proliferation in a synergistic manner. Regression diagnostics (i.e., residual plots and descriptive statistics) were used to check model assumptions. Median effect analysis was used to analyze the interaction between bortezomib and IFN-α as described by Chou and Talalay (30) . The combination index (CI) evaluates dose information for each drug alone, and in combination, at a specified effect level to identify whether two drugs act to induce apoptosis in a synergistic manner (CI<1), an additive manner (CI=1) or an antagonistic fashion (CI>1). Calcusyn software from Biosoft (Cambridge, UK) was used for this multiple drug effect analysis. The analyses for synergistic apoptosis were conducted using data obtained from Annexin V/PI assays (% apoptotic cells), and were performed under the assumption that these drugs had independent modes of action and were therefore mutually non-exclusive. Median survival time in murine experiments was estimated by the Kaplan-Meier method and comparisons overall and between groups were made using the log-rank test. The Holm procedure is a modified Bonferroni type procedure which maintains the experiment-wise error rate and was used to make adjustments for multiple comparisons between dose groups. For human xenograft studies, tumor volume data were log transformed prior to statistical analyses to stabilize the variance of the measures and improve normality. Tumor volume data between the four groups on Day 25 were compared via ANOVA with a Tukey-Kramer adjustment for multiple comparisons. A mixed effects model was used to analyze the repeated volume measurements while adjusting for the correlation within mice. All analyses were performed in SAS (version 9.1, SAS Institute, Cary, NC). Adjusted p-values were considered significant at the 0.05 level and all tests were two-sided.
RESULTS
Treatment of Melanoma and RCC Cell Lines with Bortezomib and IFN-α Leads to Enhanced Apoptotic Cell Death
The ability of both bortezomib and IFN-α to induce tumor cell apoptosis when administered as single agents led us to examine the effects of combined therapy (3, 20) . Human and murine melanoma cells were treated for 48 hours with PBS, bortezomib, IFN-α or both agents combined. Bortezomib in combination with IFN-α led to significantly increased levels of apoptosis as measured by Annexin V/PI staining compared to either agent alone in human melanoma ( 
Apoptosis Induced by Bortezomib and IFN-α is Synergistic
Using the median effect method we next assessed if bortezomib and IFN-α induced synergistic apoptosis (31) . HT144 melanoma cells were treated for 48 hours with various doses of bortezomib, IFN-α, or both agents combined (5 dose combinations) and then analyzed for apoptosis via Annexin V-PI staining. Dose-effect plots indicated that increasing the dosage of IFN-α had little effect on the induction of apoptosis, while bortezomib treatment resulted in dose-dependent increases in apoptosis ( Figure 1C ). At each paired dose, the pro-apoptotic effect was further enhanced following combined treatment with bortezomib plus IFN-α ( Figure  1C ). Dose combinations of 5 nM bortezomib and 5 × 10 3 U/mL IFN-α or greater resulted in combination indices consistently below 1.0, suggesting a dose-dependent, synergistic effect on apoptosis of HT144 melanoma cells ( Figure 1C-D) .
Combined Treatment With Bortezomib and IFN-α Induces Processing of Effector Caspases and poly (ADP-ribose) polymerase (PARP)
Enhanced processing of the major effector caspases (caspase-3, and -7) to their active forms and cleavage of poly (ADP-ribose) polymerase (PARP; a target of activated effector caspases) was observed at 48 hours following treatment of the HT144 human melanoma cell line with bortezomib plus IFN-α (Figure 2A 
Bortezomib and IFN-α induce caspase-dependent apoptosis
We next sought to determine the dependence of cell death on caspase activation. HT144 human melanoma cells were treated with PBS, IFN-α, bortezomib or both agents combined in the presence of either the pan-caspase inhibitor Z-VAD-FMK (50 μM) or Z-F-A-FMK (negative control). The pan-caspase inhibitor Z-VAD-FMK significantly inhibited apoptotic cell death at the 48 hour time point in response to bortezomib plus IFN-α (mean % of Annexin V-positive cells = 10.08% ± 3.37; n = 3 experiments, (p = 0.04) as compared to similarly treated cells cultured in the presence of the negative control compound (mean % of Annexin V-positive cells = 35.84% ± 13.85; Figure 2C and Supplementary Figure S4 ). These data suggest that the synergistic death induced by bortezomib and IFN-α is dependent on caspase activation.
Bortezomib and IFN-α can overcome elevated expression of pro-survival proteins and promote apoptosis in melanoma cells
The Bcl-2 family of mitochondrial proteins inhibit apoptosis by stabilizing the mitochondrial membrane (32) and down-regulation of these proteins has been shown to contribute to the induction of caspase-mediated apoptosis in response to bortezomib (33) . Mcl-1 promotes cell survival through its antagonistic interactions with the pro-apoptotic protein Bax, while Bcl-2 and Bcl-xL have been shown to directly antagonize Bak (34) . The Bcl-2 and Mcl-1 proteins are often over-expressed in melanoma and have been shown to affect the susceptibility of melanoma cells to apoptotic stimuli in other systems (35) (36) (37) . Decreased levels of Bcl-2 and
Mcl-1 were also observed following treatment of melanoma cell lines with bortezomib and IFN-α ( Figure 3A) . In contrast, Bcl-xL and Bax expression was not affected by treatment with bortezomib or bortezomib plus IFN-α ( Figure 3A) . The ability of this treatment combination to stimulate processing of effector caspases and down-regulate levels of pro-survival Bcl-2 and Mcl-1 proteins initially suggested that bortezomib and IFN-α might promote the intrinsic pathway of apoptosis by modulation of protein targets within the mitochondria. To further test the importance of the intrinsic pathway in mediating apoptosis, and to determine whether this treatment combination could induce apoptosis in the presence of high Bcl-2 levels, Bcl-2 was over-expressed in the human A375 melanoma cell line. Twenty-four hours following transient transfection with either the pcDNA3-Bcl-2 vector or pcDNA3 control vector, cells were treated for an additional 48 hours with PBS, bortezomib, IFN-α or both agents combined. Cells transfected with the unmodified pcDNA3 vector displayed 60% cell death and a characteristic decrease in Bcl-2 protein expression 48 hours following treatment with bortezomib plus IFN-α ( Figure 3B ). However, melanoma cells transfected with the pcDNA3-Bcl-2 construct remained sensitive to the pro-apoptotic effects of bortezomib plus IFN-α, as indicated by the cleavage of PARP (arrow; lanes 4 and 8). Also, cell death as measured by trypan blue exclusion, was only slightly reduced at 48 hours, despite the presence of high levels of Bcl-2 at all time points in all four conditions. Experiments using the pCR3.1-Mcl-1 vector indicated that melanoma cells over-expressing Mcl-1 also remained sensitive to the pro-apoptotic effects of bortezomib and IFN-α as compared to cells transfected with the negative control vector ( Figure 3C ). Interestingly, Bcl-2 and Mcl-1 levels did not decrease when cells were treated with bortezomib and IFN-α in the presence of a pan-caspase inhibitor ( Figure 3D ). These results indicated that the observed reductions in levels of Bcl-2 and Mcl-1 were likely due to the cleavage of these proteins by activated caspases and were not due to a direct modulation of Bcl-2 or Mcl-1 by bortezomib and IFN-α. Taken together, these data suggest that bortezomib and IFN-α may be an effective means of promoting cell death in cells that have developed resistance to apoptosis due to elevated expression of pro-survival proteins.
Bortezomib and IFN-α induce apoptosis via FADD-mediated caspase-8 activation
Our previous data suggested that bortezomib and IFN-α may induce apoptosis of melanoma cells through a mechanism that is independent of the mitochondrial, intrinsic pathway of apoptosis. We therefore investigated the role of the extrinsic pathway of apoptosis in mediating bortezomib and IFN-α-induced cell death. While caspase-9 is activated via the mitochondrial pathway of apoptosis, the extrinsic pathway of apoptosis involves processing of pro-caspase-8 and subsequent cleavage of Bid (a pro-apoptotic BH3-only protein) in response to the binding of death receptors by their cognate ligands (e.g. TRAIL, TNF-α, FasL) (38) . Immunoblot analysis revealed that treatment of human melanoma cell lines with bortezomib plus IFN-α led to enhanced processing of initiator caspase-8, caspase-9 and reduced levels of native Bid, a proapoptotic BH3-only protein ( Figure 4A ). The caspase-9 inhibitor Z-LEHD-FMK did not significantly inhibit apoptosis of melanoma cells in response to bortezomib and IFN-α (data not shown) however, the caspase-8 inhibitor Z-IETD-FMK significantly inhibited cell death at the 48 hour time point (mean % of Annexin V-positive cells = 20%± 5.4; n = 3 experiments) when compared to cells cultured in the presence of a negative control inhibitor (mean % of Annexin V-positive cells = 71% ± 4.2; p=.004) ( Figure 4B ). These data suggest that caspase-8 is activated first in response to treatment with bortezomib and IFN-α and that caspase-9 is processed in a secondary fashion by activated caspase-8. Interestingly, no detectable levels of TNF-α, TRAIL or FasL protein were evident in cell culture supernatants from melanoma cell lines following treatment with bortezomib and IFN-α (data not shown). While FasL and Fas proteins were detectable in whole cell lysates from untreated melanoma cell lines, treatment with bortezomib and IFN-α did not alter the expression level of these proteins in any cell line tested (data not shown).
Importantly, immunoprecipitation of cell lysates with an anti-Fas Ab followed by immunoblot analysis with an anti-FADD Ab revealed that there was a significant increase in the association between these two proteins prior to the onset of cell death following a 16 hour co-treatment with bortezomib and IFN-α ( Figure 4C ). The association of Fas and FADD and subsequent activation of caspase-8 and induction of apoptosis can occur via both FasL-dependent and FasL-independent mechanisms (39). Importantly, bortezomib and IFN-α were significantly less effective at inducing apoptosis in melanoma cells transfected with a dominant negative FADD construct that lacks the death effector domain, and therefore cannot bind pro-caspase-8 (FADDDN; Figure 4D ). Similarly, siRNA-mediated reduction of cellular Fas inhibited cell death mediated via bortezomib and IFN-α (Supplementary Figure S5) . We also observed a decrease in the basal expression of FADD in cells treated with bortezomib and IFN-α at the 48 hour time point. This event is likely due to non-specific cleavage of intracellular proteins by activated caspases as was observed for Bcl-2 and Mcl-1 ( Figure 3D ). Together these data suggest that bortezomib and IFN-α activate caspase-8 and induce apoptosis following the association of Fas and FADD.
Combined Administration of Bortezomib and IFN-α Prolongs Survival in a Murine Model of Malignant Melanoma
The effects of combined treatment with bortezomib and IFN-α were studied in an intraperitoneal (i.p.) murine model of B16 malignant melanoma in which immune competent mice routinely succumb to fatal disease burden after 12-14 days (19) 
DISCUSSION
We have demonstrated that bortezomib and IFN-α induce synergistic apoptosis in human melanoma cell lines and that cell death was dependent upon caspase activation. The proapoptotic effects of this treatment combination were significantly reduced following inhibition of caspase-8 and in the presence of a dominant negative form of the FADD protein or Fas-specific siRNA. Combined treatment with bortezomib and IFN-α also led to a significant prolongation of survival in a murine model of melanoma, and significantly reduced tumor growth in a xenograft model of human melanoma in athymic mice as compared to either agent alone. The present study demonstrates that this treatment combination may have utility for the treatment of melanoma.
Our initial experiments showed that treatment of melanoma cell lines with bortezomib and IFN-α led to processing of pro-caspase-9 and decreased levels of Bcl-2 and Mcl-1. These data suggested that the mitochondrial pathway could be involved in promoting apoptosis in response to this treatment combination (40) . Previous studies by Nencioni et al. have eloquently demonstrated that apoptosis induced by proteasome inhibition and TRAIL may involve both the cleavage of Bcl-2 to a fragment with putative pro-apoptotic activity and the elimination of anti-apoptotic Mcl-1 (33). However, Bcl-2 and Mcl-1 protein levels remained stable in the presence of a caspase inhibitor and over-expression of these pro-survival proteins or caspase-9 inhibition did not protect melanoma cells from the apoptotic program induced by bortezomib plus IFN-α. Therefore, reduced levels of these proteins in this panel of cell lines post-treatment were likely the result of non-specific cleavage by activated caspase proteins, rather than an initiating event of the apoptotic program. The activation of caspase-9 and decreased expression levels of Bcl-2 and Mcl-1 in this system likely serves to amplify the process of apoptosis once it has been initiated.
We subsequently hypothesized that this treatment combination might lead to increased production of death receptor ligands (i.e. TRAIL, TNF-α, FasL) by the melanoma cells. Previous reports have shown either bortezomib or IFN-α can activate the extrinsic pathway of apoptosis in this manner (41) . In addition, Papageorgiou et al. have demonstrated that combined therapy with IFN-α and bortezomib enhances apoptosis of human bladder cancer cell lines by a TRAIL-associated mechanism (5). Although treatment with a caspase-8 inhibitor led to a significant decrease in cell death in the present study, the endogenous expression of TRAIL, TNF-α, or FasL was not observed in either culture supernatants or lysates from melanoma cells treated with bortezomib and IFN-α (data not shown). Furthermore, previous studies have shown that TRAIL expression is not induced in A375 melanoma cells following treatment with type I IFNs (42), but A375 cells remained sensitive to the pro-apoptotic effects of combined therapy with bortezomib and IFN-α.
Despite the absence of a defined death receptor ligand, we observed an increased association between Fas and FADD in multiple melanoma cell lines prior to the onset of cell death. Furthermore, transfection of A375 melanoma cells with a FADD-DN construct or Fas-specific siRNA significantly inhibited the pro-apoptotic effects of bortezomib and IFN-α. Although increased binding between Fas and FasL can activate caspase-8 and initiate the apoptotic process (43), other reports have suggested that processing of pro-caspase-8 can be a downstream consequence of Bid cleavage (44) . However, the timing of Bid cleavage in the present model does not support this conclusion. Our data suggest that caspase-8 activation and subsequent apoptosis is initiated by Fas trimerization and its association with FADD independent of FasL (39). The precise molecular events leading to an association between Fas and FADD proteins in the present model are under investigation.
The anti-tumor properties of bortezomib have been attributed to inhibition of IκB degradation, which leads to inactivation of NF-κB, a pro-survival transcription factor that is constitutively activated in many melanoma cell lines (16, 45, 46) . However, our preliminary data indicated that bortezomib did not decrease the levels of NF-BκDNA binding or transcriptional activity in melanoma cell lines as measured by gel shift assay or analysis of NF-κB reporter activity in cells transfected with the 3xκB-Luc NF-κB promoter luciferase construct (data not shown). In addition, other groups have recently shown that inhibition of NF-κB activity accounts for only a portion of the anti-tumor activity of bortezomib (47, 48) . Previous studies by Qin et al. and Fernandez et al. have also described a role for the BH3-only protein Noxa in mediating the proapoptotic effects of proteasome inhibition in melanoma cell lines (49, 50) . However, we did not detect an increase in Noxa transcript or protein in these particular melanoma cell lines following treatment with bortezomib plus IFN-α as compared to bortezomib alone (Supplementary Figure S8) . These observations suggest that the pro-apoptotic effects of bortezomib may proceed by different mechanisms depending on the melanoma cell line under study and are augmented in a unique manner when co-administered with IFN-α.
Together these pre-clinical data suggest that combined treatment with bortezomib and IFN-α represents a novel treatment strategy for inducing a direct, pro-apoptotic effect on tumor cells. We are currently evaluating the safety and tolerability of this treatment combination in an investigator-initiated phase I clinical trial at our institution. Elucidation of the pathways of cell death induced by this treatment combination may help to identify key molecular targets that govern the viability of melanoma cells that can be further manipulated to provide an anti-tumor effect.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material. Lysates were evaluated for FADD expression (or its lower molecular weight, truncated form) and cleavage of PARP as a marker of apoptosis via immunoblot analysis. Viability of cells used to make lysates for immunoblot analysis in each experiment was evaluated using trypan blue staining. 
